ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD.

Zhejiang Tianyu Pharmaceutical Co., Ltd.

300702

CNE1000034X1

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-05-21 EDT			5-day change	1st Jan Change
20.79 ^CNY	+0.92%		-0.29%	-4.24%

05-06	China Approves Tianyu Pharma's Heart Medication	MT
04-26	Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces Profit Distribution Proposal for 2023	CI

Tranche Update on Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 30, 2022.

October 11, 2022 at 12:00 pm

From July 1, 2022 to September 30, 2022, the company has repurchased 2,009,243 shares, representing 0.58% for CNY 48.71 million. With this, the company has completed the repurchase of 2,009,243 shares, representing 0.58% for CNY 48.71 million under the buyback announced on June 30, 2022.

Latest news about Zhejiang Tianyu Pharmaceutical Co., Ltd.

China Approves Tianyu Pharma's Heart Medication	05-06	MT
Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces Profit Distribution Proposal for 2023	04-26	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-25	CI
Tranche Update on Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 24, 2024.	04-02	CI
Zhaoxin Liaowang No. 1 Private Securities Investment Fund managed by Jiangsu Zhaoxin Private Fund Management Co., Ltd. entered into a share transfer agreement to acquire 6.19% stake in Zhejiang Tianyu Pharmaceutical Co., Ltd. from Ganzhou Zhenhan Venture Capital Co., Ltd. for CNY 310 million.	03-19	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 50 million worth of its shares.	01-24	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	01-23	CI
Tianyu Pharmaceutical Unit Passes US FDA's On-Site Inspection	11-22	MT
Tianyu Pharma Unit Passes US FDA On-Site Inspection	11-20	MT
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Zhuhai Rundu Pharma Gets Supplementary Application Approval For Hypertension Drug	23-07-26	MT
Raw Drug Material of Tianyu Pharma's Unit Passes Regulatory Evaluation	23-06-16	MT
Zhejiang Tianyu Pharmaceutical Co., Ltd. announced that it expects to receive CNY 1.4 billion in funding	23-06-15	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces Management Changes	23-05-23	CI
Tianyu Pharmaceutical Unit Gets Approval to Market Hypertension Drug in China	23-05-09	MT
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Zhejiang Tianyu Pharma Unit Gets Marketing Approval For Losartan Potassium Tablets	23-02-20	MT
Tranche Update on Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 30, 2022.	22-12-15	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback announced on June 30, 2022, has expired with 2,403,643 shares, representing 0.69% for CNY 58 million.	22-12-14	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd.(SZSE:300702) dropped from Shenzhen Stock Exchange Component A Share Index	22-12-09	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd.(SZSE:300702) dropped from Shenzhen Stock Exchange Component Index	22-12-09	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-25	CI
Tranche Update on Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 30, 2022.	22-10-11	CI

Chart Zhejiang Tianyu Pharmaceutical Co., Ltd.

Duration

Period

Chart Zhejiang Tianyu Pharmaceutical Co., Ltd.

More charts

Company Profile

Zhejiang Tianyu Pharmaceutical Co Ltd is a company mainly engaged in research and development, production and sales of chemical raw materials. The Company operates three segments. The Pharmaceutical Intermediates segment include hypertension drugs raw materials, anti-asthma drugs raw materials and anticoagulant drugs raw materials. The Active Pharmaceutical Ingredients (API) segment is engaged in production of high blood pressure drug intermediates, anti-asthma drug intermediates and antiviral drug intermediates. The Company also operates Other segment. The Company sells its products to both domestic and international markets, including Europe, the United States, Japan, South Korea and so on.

Sector

Pharmaceuticals

Calendar

2024-08-26 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Zhejiang Tianyu Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

20.79 CNY

Average target price

22.6 CNY

Spread / Average Target

+8.71%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD.	-4.24%	979M
OTSUKA HOLDINGS CO., LTD.	+18.38%	22.46B
SANDOZ GROUP AG	+18.55%	15.04B
CIPLA LIMITED	+18.74%	13.98B
ZYDUS LIFESCIENCES LIMITED	+58.82%	13.15B
ONO PHARMACEUTICAL CO., LTD.	-9.78%	6.89B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.66%	5.71B
RICHTER GEDEON VEGYÉSZETI GYÁR NYILVÁNOSAN MUKÖDO RT.	+4.00%	4.69B

Generic Pharmaceuticals

Zhejiang Tianyu Pharmaceutical Co., Ltd.

Equities

300702

CNE1000034X1

Pharmaceuticals

Tranche Update on Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 30, 2022.

Latest news about Zhejiang Tianyu Pharmaceutical Co., Ltd.

Chart Zhejiang Tianyu Pharmaceutical Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Zhejiang Tianyu Pharmaceutical Co., Ltd.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Generic Pharmaceuticals